Skip to main content

Table 3 Meta-regression

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

 OR rateCR rateRR
Study (n)R2 (%)p-valueStudy (n)R2 (%)P-valueStudy (n)R2 (%)p-value
Sample size375.110.1079371.290.2262320.000.7044
Year of publication370.000.3522375.830.0905320.000.9247
Age3023.290.01033045.37< 0.0001270.000.3689
Proportion of male300.000.6095300.000.5294270.000.4814
Evaluation time293.700.2370290.000.4967270.000.6003
Follow-up time378.590.1167370.000.9396320.000.6639
Quality score370.000.1886370.100.3369320.420.3695